NewLink in RM3.27 billion deal with Roche to develop cancer drug

October 20, 2014 5:27 PM

16 0

NewLink Genetics Corp said it entered into an agreement withRoche Holding AG to develop NewLink’s cancer immunotherapy, making the Ebola vaccine developer eligible to receive over US$1 billion (RM3.27 billion) in milestone payments.

Immunotherapies are a class of drugs designed to help the body’s own immune system fend off disease.

Read more

To category page